Abstract and Findings
Confirmed infection cases in mainland China were analyzed using the data up to January 28, 2020 (first 13 days of reliable confirmed cases). In addition, all available data up to February 3 were processed the same way. For the first period the cumulative number of cases followed an exponential function. However, from January 28, we discerned a downward deviation from the exponential growth. This slower-than-exponential growth was also confirmed by a steady decline of the effective reproduction number. A backtrend analysis suggested the original basic reproduction number R0 to be about 2.4 – 2.5. We used a simple logistic growth model that fitted very well with all data reported until the time of writing. Using this model and the first set of data, we estimate that the maximum cases will be about 21,000 reaching this level in mid-February. Using all available data the maximum number of cases is somewhat higher at 29,000 but its dynamics does not change. These predictions do not account for any possible other secondary sources of infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
not applicable - all data in public domain
